| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 652.79 | 10.6% | 9.1% |
| Total Income | 652.88 | 10.5% | 8.8% |
| Expenditure | 592.47 | 9.8% | 7.0% |
| PBT | 60.41 | 18.2% | 31.7% |
| Net Profit | 45.16 | 16.3% | 29.2% |
| OPM | 12.91% | 0.36pp | 9.27pp |
| NPM | 6.92% | 2.21pp | 1.09pp |
| EPS | 4.95 | 16.2% | 29.2% |
Aarti Drugs Q2 & H1 FY26: Revenue Grows 9% YoY to Rs. 652.9 Crore, PAT Up 29% YoY
07 Nov 2025 · 7 Nov 2025, 08:44 pm
Summary
Aarti Drugs Limited, a Mumbai based diversified and fully integrated pharmaceutical company, has announced its unaudited financial results for the quarter and half year ended 30th September 2025. The company reported a 9% YoY growth in revenue, with EBITDA and PAT also showing significant increases.
Key Highlights
- 1
Revenue for Q2 FY26 stood at Rs. 652.9 crore, a 9% YoY growth
- 2
EBITDA for Q2 FY26 stood at Rs. 84.4 crore, a 23% YoY increase
- 3
PAT for Q2 FY26 stood at Rs. 45.2 crore, a 29% YoY increase
- 4
H1 FY26 revenue stood at Rs. 1,243.7 crore, an 8% YoY growth
- 5
H1 FY26 EBITDA stood at Rs. 158.8 crore, an 18% YoY increase
- 6
H1 FY26 PAT stood at Rs. 99.1 crore, a 45% YoY increase
- 7
API segment contributed 515.9 crores to Q2 FY26 revenue
- 8
Formulations segment contributed 82.4 crores to Q2 FY26 revenue
- 9
Specialty Chemicals segment contributed 37.3 crores to Q2 FY26 revenue
- 10
Intermediates & Others segment contributed 21.3 crores to Q2 FY26 revenue
- 11
Standalone business contributed 89% to the consolidated revenue
- 12
Domestic revenue was down 7% YoY and export revenue increased by 33% YoY
Management Comments
Mr. Adhish Patil
CFO & COO, Aarti Drugs Limited
We are pleased with the operational progress achieved during the quarter. Aarti Drugs posted revenue of Rs. 652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 23%, with margin at 12.9%. For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% year-on-year, with EBITDA of Rs. 158.8 crore, up 18% with margin at 12.8%.
Informational and educational content only. Not investment advice.